long intergenic non-protein coding RNA 2353Genealiases: []
Q-omics provides the consensus-scored LINC02353 profile across patient tissues and cancer cell-line models. LINC02353 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC02353 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, LINC02353 RNA expression shows 6,288 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRP, HNSC, and LIHC as cancer lineages where LINC02353 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02353 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02353 survival associations across molecular data types. LINC02353 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02353 RNA expression–survival associations across cancer types. High LINC02353 expression shows unfavorable associations in KIRP, LIHC, STAD, TGCT and LUAD, but favorable associations in SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC02353 RNA expression.
This table summarizes LINC02353 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02353. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02353 shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher LINC02353 RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .016).
This table shows molecular features associated with LINC02353 in patient tissues and cancer cell lines. In patient samples, LINC02353 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
